26% P<0.0001 REDUCTION in
hospitalization for worsening heart failure
hospitalization for worsening heart failure
26% P=0.014 REDUCTION
in death for heart failure
in death for heart failure
Mortality and hospitalization outcomes
Effect of ivabradine on outcomes
|
||
Hazard ratio | P value | |
All-cause mortality | 0.90 | 0.092 |
CV mortality | 0.91 | 0.128 |
All-cause hospital admission | 0.89 | 0.003 |
Any CV hospital admission | 0.85 | 0.0002 |
CV death/ hospital admission for heart failure or nonfatal myocardial infarction | 0.82 | <0.0001 |
Others
- In the subgroup of patients receiving at least 50% of the evidence-based target daily dose of a β-blocker:
– the effects of ivabradine were consistent with the overall findings, though less marked
– the primary end point and mortality components were not significantly reduced
– 19% reduction of hospital admissions for worsening heart failure with ivabradine. - Significant improvement of NYHA class with ivabradine.
- Greater improvement of patient-reported global assessment & physician-reported assessment with ivabradine.1
1. Swedberg K, et al. Lancet. 2010;376(9744):875-885.